Page 3 - Eddiej Sullivan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SAB Biotherapeutics : Change in Certifying Accountants - Form 8-K -Today at 08:48 am

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to.

United statesSouth dakotaSioux fallsEddiej sullivanMayer hoffman mccannAudit committeeNasdaq stock marketExchange commission the onCompany quarterly report on formSecurities exchangeCompany current report on formCommission file numberBiotherapeutics incSecurities exchange actIts charterPrincipal executive offices

SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results

SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency,

United statesMichael hallerEddiej sullivanExchange commissionInternational conventionDiabetes research foundationDevelopment rd expensesBiotherapeutics incFederation of clinical immunology societiesUniversity of floridaDrug administrationInternational society for influenzaClinical immunology societiesChief executive officerInternational societyNew animal drug application

SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention

SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering influenza therapeutic, SAB-176SIOUX. | May 30, 2023

United statesEddiej sullivanSheila carlsonEddie sullivanBiotherapeutics incExhibition centerBiotechnology innovation organizationBoston conventionDrug administrationInternational conventionExchange commissionChief executive officer eddie sullivanChief executive officerBreakthrough therapyFast track designationsPrivate securities litigation reform act

SAB Biotherapeutics Announces Progress on U S FDA s Phased Review of Company s Groundbreaking DiversitAb™ Platform

- FDA has approved five of seven sections in a rolling submission required for a New Animal Drug Application for Company’s antibody generating DiversitAb™ platform in. | May 9, 2023

Eddiej sullivanAlexandra kropotovaExchange commissionBiotherapeutics incDrug administrationNational institutes of healthCompany tcNew animal drug applicationBiologics license applicationsBiologics evaluationChief executive officerVeterinary medicineChief medical officerBreakthrough therapyFast trackPrivate securities litigation reform act

SAB Biotherapeutics (SABS) Reports Positive Results from Phase 3 Trial of SAB-185

SAB Biotherapeutics (SABS) Reports Positive Results from Phase 3 Trial of SAB-185
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Eddiej sullivanAlexandra kropotovaBiotherapeutics incNational institutes of healthHealth affairsDevelopment authorityNuclear defenseExchange commissionOffice of theBiomedical advanced researchDepartment of healthHuman servicesDefense health agencySymptom resolution overSymptom resolutionSafety monitoring board